|
所属 |
医学部 附属病院 卒後臨床研修センター |
|
職名 |
助教 |
|
外部リンク |
|
|
関連SDGs |
|
論文 【 表示 ／ 非表示 】
-
Oda Y., Tsubouchi H., Ishii N., Kitamura A., Moriyama E., Mitsutome E., Sakai K., Shiomi K., Yanagi S., Miyazaki T.
Respiratory Medicine Case Reports 46 101930 2023年10月
担当区分：筆頭著者, 責任著者 記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Respiratory Medicine Case Reports
Small cell lung carcinoma (SCLC) is a neuroendocrine carcinoma with a poor prognosis and is a common cause of paraneoplastic syndromes. Paraneoplastic syndromes are characterized by neurological and endocrinological problems in patients with malignancy and are often associated with difficulty in induction of chemotherapy. Here we report the case of a patient with SCLC concomitant with two paraneoplastic syndromes, syndrome of inappropriate antidiuretic hormone secretion (SIADH) and Lambert–Eaton myasthenic syndrome (LEMS), who was treated with a platinum-doublet chemotherapy regimen. A 66-year-old male patient presented with a 1-month history of progressive proximal muscle weakness, ataxia gait and 5 kg of body weight loss. The laboratory tests revealed hyponatremia due to SIADH and the existence of antibodies against P/Q-type voltage-gated calcium channels. The nerve conduction study showed a low amplitude of compound muscle action potential (0.38 mv), a 34% decrement on 3-Hz stimulation, and a 1939% increment after maximum voluntary contraction in 10 seconds (7.75 mv). The endobronchial ultrasound transbronchial needle aspiration biopsy revealed the pathological findings of SCLC. A 2-cycle chemotherapy regimen of irinotecan plus cisplatin resulted in temporary tumor shrinkage that lasted 2 months, but the improvement of proximal muscle weakness and hyponatremia were maintained over the tumor re-progression period after chemotherapy. Although paraneoplastic syndromes accelerate the decrease in performance status, chemotherapy for SCLC may improve symptoms related to paraneoplastic syndromes and could be considered in similar cases.
-
悪性胸水に対するTalcとOK-432による胸膜癒着術の検討． 査読あり
小田康晴、松元信弘、瀬戸口健介、宇都加寿子、重草貴文、松尾彩子、坪内拡伸、坂元昭裕、今津善史、有村保次、柳 重久、飯干宏俊、中里雅光
宮崎県医師会医学会誌 42 17 - 21 2018年
担当区分：筆頭著者, 責任著者 記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Cerebral radiation necrosis successfully treated with high-dose bevacizumab 査読あり
Kugimiya K., Tsubouchi H., Saito K., Kadota Y., Azuma M., Sakai K., Oda Y., Sumiyoshi M., Yanagi S., Miyazaki T.
Respiratory Medicine Case Reports 58 102282 2025年1月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Respiratory Medicine Case Reports
Cerebral radiation necrosis (CRN) is a late complication that can occur after the treatment of a brain tumor with focal radiation therapy, particularly stereotactic radiosurgery (SRS). Since an excessive production of vascular endothelial growth factor (VEGF) from necrotic lesions is a possible etiology of radiation necrosis, the anti-VEGF antibody bevacizumab has been reported as an effective treatment option. We report a case of a 71-year-old Japanese male with CRN following SRS, successfully treated with bevacizumab. He had presented with aphasia and right lower-limb muscle weakness 6 years after a left upper lobectomy for lung adenocarcinoma. Head magnetic resonance imaging (MRI) showed a metastatic brain tumor in the left temporal lobe. A craniotomy and pre- and post-operative SRS treatments were performed to relieve his neurological symptoms. Although initial symptom improvement was observed, the patient developed lower-limb muscle weakness and aphasia symptoms 7 months after the last SRS treatment.<sup>11</sup>C-methionine positron emission tomography (PET) and<sup>18</sup>F-fluorodeoxyglucose PET scans showed no abnormal uptake, leading to a diagnosis of CRN. The patient was treated with bevacizumab 15 mg/kg every 3 weeks for six cycles. The bevacizumab treatment resulted in an improvement of neurological symptoms and lesions showing gadolinium-enhancing effects and high-signal areas on T2-weighted fluid attenuated inversion recovery on MRI. The improvement was maintained 44 months after the completion of the last bevacizumab treatment. Although no definitive number of cycles and dosage of bevacizumab for CRN have been established, this case suggests that administering six cycles of bevacizumab may prevent long-term recurrence of CRN.
-
Cerebral radiation necrosis successfully treated with high-dose bevacizumab 査読あり
釘宮 啓一, 坪内 拡伸, 門田 善仁, 東 美菜子, 酒井 克也, 小田 康晴, 住吉 誠, 柳 重久, 宮崎 泰可
Respiratory medicine case reports 58 102282 2025年
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Elsevier
Cerebral radiation necrosis (CRN) is a late complication that can occur after the treatment of a brain tumor with focal radiation therapy, particularly stereotactic radiosurgery (SRS). Since an excessive production of vascular endothelial growth factor (VEGF) from necrotic lesions is a possible etiology of radiation necrosis, the anti-VEGF antibody bevacizumab has been reported as an effective treatment option. We report a case of a 71-year-old Japanese male with CRN following SRS, successfully treated with bevacizumab. He had presented with aphasia and right lower-limb muscle weakness 6 years after a left upper lobectomy for lung adenocarcinoma. Head magnetic resonance imaging (MRI) showed a metastatic brain tumor in the left temporal lobe. A craniotomy and pre- and post-operative SRS treatments were performed to relieve his neurological symptoms. Although initial symptom improvement was observed, the patient developed lower-limb muscle weakness and aphasia symptoms 7 months after the last SRS treatment. 11C-methionine positron emission tomography (PET) and 18F-fluorodeoxyglucose PET scans showed no abnormal uptake, leading to a diagnosis of CRN. The patient was treated with bevacizumab 15 mg/kg every 3 weeks for six cycles. The bevacizumab treatment resulted in an improvement of neurological symptoms and lesions showing gadolinium-enhancing effects and high-signal areas on T2-weighted fluid attenuated inversion recovery on MRI. The improvement was maintained 44 months after the completion of the last bevacizumab treatment. Although no definitive number of cycles and dosage of bevacizumab for CRN have been established, this case suggests that administering six cycles of bevacizumab may prevent long-term recurrence of CRN.
-
Mitsutome E., Yanagi S., Uchida T., Horiguchi T., Tsubouchi H., Sumiyoshi M., Kitamura A., Oda Y., Ueno H., Yamaguchi H., Miyazaki T.
Journal of Infection and Chemotherapy 31 ( 1 ) 102482 2024年
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Infection and Chemotherapy
Most cases of nontuberculous mycobacterial pulmonary disease (NTM-PD) have a progressive clinical course, and initiation of treatment is recommended rather than watchful waiting. The NTM-PD medications are frequently associated with adverse reactions, occasionally serious. Optimization of the methods for monitoring and managing adverse events in NTM-PD treatment is thus an important medical issue. Here we report a first case of postprandial hypoglycemia caused by the combination of clarithromycin (CAM) and rifampicin (RFP) in a patient with NTM-PD. A 73-year-old Japanese woman with NTM-PD was hospitalized for treatment with a combination of oral CAM, RFP, and ethambutol. She took the first doses of antibiotics before breakfast, and 3 h later went into a hypoglycemic state. Postprandial hypoglycemia occurred with high reproducibility and was accompanied by relative insulin excess. Continuous glucose monitoring with or without food and in combination with various patterns of medication revealed that the combination of CAM and RFP specifically induced postprandial hypoglycemia. Shifting the timing of administration of the CAM and RFP combination from morning to before sleep corrected the hypoglycemia and enabled continuation of the antimicrobial treatment. In conclusion, our report suggests the importance of introducing NTM-PD medication under inpatient management in order to closely monitor and early detect postprandial hypoglycemia and other serious adverse events.
講演・口頭発表等 【 表示 ／ 非表示 】
-
IV期EGFR陽性肺腺癌の転移性縦隔リンパ節が小細胞癌に転化した一例
大槻佑生子、堀口崇典、小田康晴、北村 彩、重草貴文、土田真平、坪内拡伸、柳 重久、松元信弘、宮崎泰可
第62回日本呼吸器学会学術講演会
開催年月日： 2022年4月22日 - 2022年4月24日
会議種別：口頭発表（一般）
-
当院で検出したEGFR遺伝子変異陽性肺腺癌におけるuncommon mutation症 例の報告
土田真平、北村 彩、堀口崇典、重草貴文、小田康晴、坪内拡伸、柳 重久、松元信弘、宮﨑泰可
第88回日本呼吸器学会・日本結核非結核性抗酸菌症病学会九州支部春季各術講演会
開催年月日： 2022年3月19日
会議種別：口頭発表（一般）
-
蘇生的開胸術後に左上葉肺捻転を起こした一例
北村 彩、小田康晴、宗像 駿、前田 亮、富田雅樹、堀口崇典、坪内拡伸、柳 重久、松元信弘、宮崎泰可
第88回日本呼吸器学会・日本結核非結核性抗酸菌症病学会九州支部春季各術講演会
開催年月日： 2022年3月19日
会議種別：口頭発表（一般）
-
デキサメタゾン投与下で両側副腎転移によるAddiso病が疑われた肺腺癌の1例
瀬戸暁子、堀口崇典、内田泰介、重草貴文、土田真平、小田康晴、坪内拡伸、柳 重久、松元信弘、宮崎泰可
第335回日本内科学会九州地方会
開催年月日： 2021年11月14日
会議種別：口頭発表（一般）
-
胸部外科手術後に放線菌による皮下膿瘍を発症した1例
山田愛加理、北村 彩 、堀口崇典、土田真平、重草貴文、小田康晴、坪内拡伸、柳 重久、松元信弘、宮崎泰可
第335回日本内科学会九州地方会
開催年月日： 2021年11月14日
会議種別：口頭発表（一般）
科研費（文科省・学振・厚労省）獲得実績 【 表示 ／ 非表示 】
-
自然肺腺癌モデルマウスの1細胞解析で発見した間葉亜集団の発癌への必須性の解明
研究課題/領域番号：24K11319 2024年04月 - 2027年03月
独立行政法人日本学術振興会 科学研究費基金 基盤研究(C)
担当区分：研究分担者
-
オクタン酸トリグリセリドを用いた呼吸不全カヘキシア包括的治療法の開発研究
研究課題/領域番号：21K11264 2021年04月 - 2024年03月
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
松元 信弘
担当区分：研究分担者
-
1細胞解析結果に基づく肺癌の発癌責任間葉サブクラスターとCAF起源細胞の決定
研究課題/領域番号：21K08159 2021年04月 - 2024年03月
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
柳 重久、坪内 拡伸、小田 康晴
担当区分：研究分担者